Bausch + Lomb has announced its fourth-quarter and full-year 2025 financial results and also provided 2026 guidance. The company reported revenue growth across all business segments in both the fourth quarter and for the full-year, including increases in vision care, surgical and pharmaceutical. During the fourth quarter, revenue increased by 10 percent to $1.405 billion from $1.280 billion in 2024. For the full year 2025, revenue grew by 6 percent, reaching $5.101 billion compared with $4.791 billion in 2024. The company reported strong growth in its vision care segment, primarily driven by what it said was growth in contact lenses and key consumer franchises, including Lumify and over-the-counter dry eye products. In dry eye, Miebo sales reached $112 million in the fourth quarter and total dry eye portfolio revenue was $1.1 billion in 2025, the company reported. Bausch + Lomb’s Chairman and Ceo Brent Saunders said: “We didn’t just grow in the fourth quarter, we grew smarter and faster than the market. Meaningful ebitda margin expansion and operating leverage is a clear sign of our commitment to financial excellence.”

March 2026